Once-monthly paliperidone injection for the treatment of schizophrenia

Delia BisharaPharmacy Department, South London and Maudsley NHS Foundation Trust, London, United KingdomAbstract: Paliperidone palmitate is a new long-acting antipsychotic injection for the treatment of acute and maintenance therapy in schizophrenia. Paliperidone (9-hydroxyrisperidone) is the major...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Delia Bishara
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b457f0bcc8a3435f94ea09d714e9c6a8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b457f0bcc8a3435f94ea09d714e9c6a8
record_format	dspace
spelling	oai:doaj.org-article:b457f0bcc8a3435f94ea09d714e9c6a82021-12-02T02:04:06ZOnce-monthly paliperidone injection for the treatment of schizophrenia1176-63281178-2021https://doaj.org/article/b457f0bcc8a3435f94ea09d714e9c6a82010-09-01T00:00:00Zhttp://www.dovepress.com/once-monthly-paliperidone-injection-for-the-treatment-of-schizophrenia-a5180https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Delia BisharaPharmacy Department, South London and Maudsley NHS Foundation Trust, London, United KingdomAbstract: Paliperidone palmitate is a new long-acting antipsychotic injection for the treatment of acute and maintenance therapy in schizophrenia. Paliperidone (9-hydroxyrisperidone) is the major active metabolite of risperidone and acts at dopamine D2 and serotonin 5HT2A receptors. As with other atypical antipsychotics, it exhibits a high 5HT2A:D2 affinity ratio. It also has binding activity as an antagonist at &alpha;1- and &alpha;2 adrenergic receptors and H1 histaminergic receptors, but has virtually no affinity for cholinergic receptors. Paliperidone palmitate has been shown to be effective in reducing Positive and Negative Syndrome Scale total scores in four short-term trials in acute schizophrenia. It was also effective as maintenance therapy in a long-term trial in which time to recurrence of symptoms was significantly longer in paliperidone-treated patients compared with placebo. In addition, paliperidone was shown to be noninferior to risperidone long-acting injection in one study, but this noninferiority was not established in another longer study comparing the two drugs. Treatment should be initiated with 234 mg on day 1 and 156 mg on day 8, followed by a recommended monthly maintenance dose of 39&ndash;234 mg based on efficacy and tolerability. Paliperidone palmitate is generally well tolerated, although it can cause weight gain and a rise in prolactin levels, which is generally greater in women than in men. Overall, paliperidone palmitate may have advantages over other currently available long-acting injections, and therefore may be a useful alternative for the treatment of schizophrenia, although further long-term trials comparing it with active treatments are warranted.Keywords: paliperidone palmitate, injection, schizophrenia, long-acting Delia BisharaDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 561-572 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Delia Bishara Once-monthly paliperidone injection for the treatment of schizophrenia
description	Delia BisharaPharmacy Department, South London and Maudsley NHS Foundation Trust, London, United KingdomAbstract: Paliperidone palmitate is a new long-acting antipsychotic injection for the treatment of acute and maintenance therapy in schizophrenia. Paliperidone (9-hydroxyrisperidone) is the major active metabolite of risperidone and acts at dopamine D2 and serotonin 5HT2A receptors. As with other atypical antipsychotics, it exhibits a high 5HT2A:D2 affinity ratio. It also has binding activity as an antagonist at &alpha;1- and &alpha;2 adrenergic receptors and H1 histaminergic receptors, but has virtually no affinity for cholinergic receptors. Paliperidone palmitate has been shown to be effective in reducing Positive and Negative Syndrome Scale total scores in four short-term trials in acute schizophrenia. It was also effective as maintenance therapy in a long-term trial in which time to recurrence of symptoms was significantly longer in paliperidone-treated patients compared with placebo. In addition, paliperidone was shown to be noninferior to risperidone long-acting injection in one study, but this noninferiority was not established in another longer study comparing the two drugs. Treatment should be initiated with 234 mg on day 1 and 156 mg on day 8, followed by a recommended monthly maintenance dose of 39&ndash;234 mg based on efficacy and tolerability. Paliperidone palmitate is generally well tolerated, although it can cause weight gain and a rise in prolactin levels, which is generally greater in women than in men. Overall, paliperidone palmitate may have advantages over other currently available long-acting injections, and therefore may be a useful alternative for the treatment of schizophrenia, although further long-term trials comparing it with active treatments are warranted.Keywords: paliperidone palmitate, injection, schizophrenia, long-acting
format	article
author	Delia Bishara
author_facet	Delia Bishara
author_sort	Delia Bishara
title	Once-monthly paliperidone injection for the treatment of schizophrenia
title_short	Once-monthly paliperidone injection for the treatment of schizophrenia
title_full	Once-monthly paliperidone injection for the treatment of schizophrenia
title_fullStr	Once-monthly paliperidone injection for the treatment of schizophrenia
title_full_unstemmed	Once-monthly paliperidone injection for the treatment of schizophrenia
title_sort	once-monthly paliperidone injection for the treatment of schizophrenia
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/b457f0bcc8a3435f94ea09d714e9c6a8
work_keys_str_mv	AT deliabishara oncemonthlypaliperidoneinjectionforthetreatmentofschizophrenia
_version_	1718402728118452224

Once-monthly paliperidone injection for the treatment of schizophrenia

Ejemplares similares